Form 4: Ionis Pharma Exec Reports Stock Transactions
Insider Transaction Report
Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, reported the vesting of restricted stock units, a new grant of performance and regular restricted stock units, and a sale of shares to cover tax obligations.
Summary
- Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals Inc. (IONS), reported multiple transactions involving common stock and restricted stock units.
- On January 15, 2026, 17,377 shares of common stock were acquired due to the vesting and release of Restricted Stock Unit (RSU) awards.
- On January 16, 2026, 8,353 shares of common stock were sold at a weighted average price of $75.95 per share to cover required tax withholding obligations.
- A grant of 25,800 Performance Restricted Stock Units (PRSUs) was made on January 15, 2026, which may vest over a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group. This number represents the maximum possible vesting (200% of target).
- An additional grant of 9,675 Restricted Stock Units (RSUs) was made on January 15, 2026, which will vest in four equal annual installments.
- Following these transactions, Devers beneficially owns 26,518 shares of common stock, 47,800 Performance Restricted Stock Units, and 52,704 Restricted Stock Units.
Sentiment
Score: 7
Explanation: The filing reflects routine executive compensation activities, including the vesting of existing equity and the grant of new performance-based and time-based restricted stock units, which are generally positive for executive alignment. The sale of shares was for tax purposes, a standard practice.
Positives
- Shannon L. Devers received a grant of 25,800 Performance Restricted Stock Units (PRSUs), indicating continued incentive alignment with company performance.
- An additional 9,675 Restricted Stock Units (RSUs) were granted, further aligning executive compensation with long-term company success.
- 17,377 shares of common stock vested from previous RSU awards, representing a realization of prior compensation.
Negatives
- 8,353 shares of common stock were sold to cover tax withholding obligations, reducing the direct beneficial ownership of common stock.
Risks
- The vesting of 25,800 Performance Restricted Stock Units (PRSUs) is contingent on the Issuer's relative total shareholder return compared to a peer group over a three-year period, meaning actual vesting could range from zero to the stated maximum.
Future Outlook
The future vesting of Performance Restricted Stock Units is tied to Ionis Pharmaceuticals' relative total shareholder return against a peer group over a three-year period, indicating a forward-looking incentive structure for executive compensation.
Industry Context
This filing details routine executive equity compensation and tax-related stock transactions, which are common practices across the biotechnology and pharmaceutical industries to align executive incentives with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reference to Existing Policy | All equity transactions, including the grant of Performance Restricted Stock Units and Restricted Stock Units, were conducted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. | N/A | Confirms adherence to established corporate governance policies regarding executive compensation and equity incentives. |
Stakeholder Impact
- Shareholders: The executive's equity holdings and new grants align their interests with long-term shareholder value creation.
- Employees: The filing reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.
Next Steps
- Future vesting of 25,800 Performance Restricted Stock Units (PRSUs) on 01/15/2029, contingent on relative total shareholder return.
- Future vesting of 9,675 Restricted Stock Units (RSUs) in four equal annual installments starting from 01/15/2027.
Key Dates
| Date | Description |
|---|---|
| 01/15/2026 | Acquisition of 17,377 common shares from RSU vesting; Grant of 25,800 Performance Restricted Stock Units (PRSUs); Grant of 9,675 Restricted Stock Units (RSUs); Vesting of 17,377 Restricted Stock Units. |
| 01/16/2026 | Sale of 8,353 common shares for tax withholding. |
| 01/20/2026 | Date the Form 4 was signed. |
| 01/15/2027 | Expected first annual vesting installment for 9,675 RSUs (based on four equal annual installments from 01/15/2026 grant date). |
| 01/15/2029 | Expiration date for Performance Restricted Stock Units (end of three-year performance period). |
Recommendation
holdThis Form 4 details routine executive equity compensation and tax-related stock transactions. While new equity grants align executive interests with long-term company performance, the filing does not contain information on the company's operational or financial performance that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as it reflects a neutral stance based solely on the information presented in this specific filing.
Keywords
IONIS PHARMACEUTICALS, IONS, Form 4, insider trading, stock transactions, executive compensation, restricted stock units, performance restricted stock units, equity incentive plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.